Industry Trend Analysis - CRISPR Potential Broadens As Research Accelerates - OCT 2017

BMI View: CRISPR technology will be embraced by big pharma , and Merck KGaA is amongst the first to bring the tec hnology in-house. Patent fights will ensue, unlikely producing a clear winner, resulting in cross-licensing deals . The breadth of potential targets with CRISPR, as highlighted by the significant preclinical results, will continue to attract attention , with rare diseases and cancer being the first targets that will make it through the clinic.

The European Patent Office (EPO) has issued a 'Notice of Intention to Grant' for Merck KGaA's patent application covering the company's CRISPR technology used in a genomic integration method for eukaryotic cells. The patent will provide Merck's CRISPR genomic integration technology with broad protection, further strengthening the company's patent portfolio. A related patent was approved in Australia in June 2017.

Merck Has Strong Heritage In Gene Editing

This article is part of our Emerging Europe coverage. To access this article subscribe now or sign up for free trial